Mycotherapy: Potential of Fungal Bioactives for the Treatment of Mental Health Disorders and Morbidities of Chronic Pain

Mushrooms have a long history of traditional medicinal use and are the primary natural source of psychedelic compounds. Growing interest focuses on using fungal active compounds like psychedelics to alleviate symptoms of mental health disorders such as major depressive disorder, anxiety, and addiction. The anxiolytic, antidepressant, and anti-addictive effects of these compounds have spurred neuropharmacological investigations. Micro-dosing or acute dosing with psychedelics like LSD and psilocybin may offer treatment options for patients who do not benefit from current therapies. Studies suggest that either dosing regimen produces a rapid and long-lasting effect with a good safety profile.

Study at a glance

Abstract

Mushrooms have been used as traditional medicine for millennia, fungi are the main natural source of psychedelic compounds. There is now increasing interest in using fungal active compounds such as psychedelics for alleviating symptoms of mental health disorders including major depressive disorder, anxiety, and addiction. The anxiolytic, antidepressant and anti-addictive effect of these compounds has raised awareness stimulating neuropharmacological investigations. Micro-dosing or acute dosing with psychedelics including Lysergic acid diethylamide (LSD) and psilocybin may offer patients treatment options which are unmet by current therapeutic options. Studies suggest that either dosing regimen produces a rapid and long-lasting effect on the patient post administration with a good safety profile. Psychedelics can also modulate immune systems including pro-inflammatory cytokines suggesting a potential in the treatment of auto-immune and other chronic pain conditions. This literature review aims to explore recent evidence relating to the application of fungal bioactives in treating chronic mental health and chronic pain morbidities.